Cyclin-dependent protein kinases as therapeutic drug targets for antimalarial drug development

Bibliography

• BREMAN JG: The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. Am.j Trop. Med. Hyg. (2001) 64\(Suppl. 1–2):1–11.
   Google Scholar
• ••Explains the widespread problems of malaria.
   Google Scholar
• TRAPE JF, PISON G, SPIEGEL A et al.: Combating malaria in Africa. Trends Parasitol (2002) 18:224–230.
   PubMed Web of Science ®Google Scholar
• WINSTANLEY PA, WARD SA, SNOW RW: Clinical status and implications of antimalarial drug resistance. Microbes Infect. (2002) 4:157–164.
   PubMed Web of Science ®Google Scholar
• WONGSRICHANALAI C, PICKARD AL,WERNSDORFER WH et al.: Epidemiology of drug-resistant malaria. Lancet Infect. Dis. (2002) 2:209–218.
   PubMed Web of Science ®Google Scholar
• •Reveals the ongoing development of drug-resistant malaria.
   Google Scholar
• BLOLAND PB, LACKRITZ EM, KAZEMBE PN et al.: Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. Infect. Dis. (1993) 167:932–937.
   Web of Science ®Google Scholar
• SHRETTA R, OMUMBO J, RAPUODA Bet al.: Using evidence to change antimalarial drug policy in Kenya. Trop. Med. mt. Health (2000) 5:755–764.
   Google Scholar
• SIBLEY CH, HYDE JE, SIMS PF et al: Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? Trends Parasitol (2001) 17:582–588.
   PubMed Web of Science ®Google Scholar
• HYDE JE: Mechanisms of resistance of Plasmodium falciparum to antimalarial drugs. Microbes Infect. (2002) 4:165–174.
   PubMed Web of Science ®Google Scholar
• RIDLEY RG: Plasmodium: drug discovery and development — an industrial perspective. Exp. Parasitol (1997) 87:293–304.
   PubMed Web of Science ®Google Scholar
• OLLIARO PL, YUTHAVONG Y: An overview of chemotherapeutic targets for antimalarial drug discovery. Pharmacol Ther. (1999) 81:91–110.
   PubMed Web of Science ®Google Scholar
• •A synopsis of a few current antimalarial drug targets that are being developed to design inhibitors.
   Google Scholar
• DAMIENS E, MEIJER L: Chemical inhibitors of cyclic-dependent kinases:
   Google Scholar
• •• preclinical and clinical study. Pathol Biol. (2000) 48:340–351.
   Google Scholar
• GARRETT MD, WORKMAN P: Discovering novel chemotherapeutic drugs for the third millennium. Eur. I Cancer (1999) 35:2010–2030.
   PubMed Web of Science ®Google Scholar
• HAJDUCH M, HAVLIEEK L, VESELY J et al.: Synthetic cyclin-dependent kinase inhibitors. New generation of potent anti-cancer drugs. Adv. Exp. Med. Biol. (1999) 457:341–353.
   PubMed Web of Science ®Google Scholar
• MEIJER L, LECLERC S, LEOST M: Properties and potential-applications of chemical inhibitors of cyclin-dependent kinases. Pharmacol Ther. (1999) 82:279–284.
   PubMed Web of Science ®Google Scholar
• GRAY N, DETIVAUD L, DOERIG C et al.: ATP-site directed inhibitors of cyclin-dependent kinases. Curr. Med. Chem. (1999) 6:859–875.
   PubMed Web of Science ®Google Scholar
• MORGAN DO: Cyclin-dependent kinases: engines, clocks, and microprocessors. Ann. Rev Cell Dev. Biol. (1997) 13:261–291.
   PubMed Web of Science ®Google Scholar
• NURSE P: Ordering S phase and M phase in the cell cycle. Cell (1994) 79:547–550.
   PubMed Web of Science ®Google Scholar
• MORGAN DO: Principles of CDK regulation. Nature (1995) 374:131–134.
   PubMed Web of Science ®Google Scholar
• •Describes the various mechanisms of CDK regulation.
   Google Scholar
• JEFFREY PD, RUSSO AA, POLYAK K et al.: Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature (1995) 376:313–320.
   PubMed Web of Science ®Google Scholar
• DE BONDT HL, ROSENBLATT J, JANCARIK J et al.: Crystal structure of cyclin-dependent kinase 2. Nature (1993) 363:595–602.
   PubMed Web of Science ®Google Scholar
• PAVLETICH NP: Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J. Ma Biol. (1999) 287:821–828.
   Google Scholar
• LEE MG, NURSE P: Complementation used to clone a human homologue of the fission yeast cell cycle control gene cdc2. Nature (1987) 327(6117):31–35.
   PubMed Web of Science ®Google Scholar
• MEIJER L: Chemical inhibitors of cyclin-dependent kinases. Frog. Cell Cycle Res. (1995) 1:351–363.
   PubMedGoogle Scholar
• FISCHER PM, LANE DP: Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics. Curr. Med. Chem. (2000) 7:1213–1245.
   PubMed Web of Science ®Google Scholar
• ••A review of CDK inhibitors.
   Google Scholar
• HARDCASTLE IR, GOLDING BT, GRIFFIN RJ: Designing inhibitors of cyclin-dependent kinases. Ann. Rev Pharmacol Toxicol (2002) 42:325-348. A review of CDK inhibitors.
   Google Scholar
• CARINI DJ, KALTENBACH RE LIU J et al.: Identification of selective inhibitors of cyclin-dependent kinase 4. Bioorg. Med. Chem. Lett (2001) 11:2209–2211.
   Google Scholar
• KIM KS, SACK JS, TOKARSKI JS et al.: Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects. Med. Chem. (2000) 43:4126–4134.
   Web of Science ®Google Scholar
• ARNOT DE, GULL K: The Plasmodium cell-cycle: facts and questions. Ann. Trop. Med. Parasitol (1998) 92:361–365.
   PubMedGoogle Scholar
• LEETE TH, RUBIN H: Malaria and the cell cycle. Parasitol Today (1996) 12:442–444.
   PubMedGoogle Scholar
• DOERIG C, CHAKRABARTI D, KAPPES B et al: The cell cycle in protozoan parasites. Frog. Cell Cycle Res. (2000) 4:163–183.
   PubMedGoogle Scholar
• ••A review on the processes of cellulardivision in P falciparum.
   Google Scholar
• DOERIG C, HORROCKS P, COYLE J et al: Pfcrk-1, a developmentally regulated cdc2-related protein kinase of Plasmodium fakiparum. Mol. Biochem. Parasitol (1995) 70:167–174.
   PubMed Web of Science ®Google Scholar
• ROSS-MACDONALD PB, GRAESER R, KAPPES B et al: Isolation and expression of a gene specifying a cdc2-like protein kinase from the human malaria parasite Plasmodium falcipamm. Eur. Biochem. (1994) 220:693–701.
   PubMedGoogle Scholar
• GRAESER R, FRANKLIN RIVI, KAPPES B: Mechanisms of activation of the cdc2-related kinase PfPK5 from Plasmodium fakiparum. Mol. Biochem. Parasitol (1996) 79:125–127.
   PubMed Web of Science ®Google Scholar
• GRAESER R, WERNLI B, FRANKLIN RIVI et al: Plasmodium fakiparum protein kinase 5 and the malarial nuclear division cycles. Ma Biochem. Parasitol (1996) 82:37–49.
   PubMed Web of Science ®Google Scholar
• ••Describes a possible role of PfPK5 in theregulation of DNA replication in the parasite.
   Google Scholar
• BRACCHI-RICARD V, BARIK S, DELVE CCHIO C et al.: PfPK6, a novel cyclin-dependent kinase/mitogen-activated protein kinase-related protein kinase from Plasmodium falcipamm. Biochem. 1 (2000) 347 Pt 1:255–263.
   Google Scholar
• LE ROCH K, SESTIER C, DORIN D et al.: Activation of a Plasmodium falcipamm cdc2-related kinase by heterologous p25 and cyclin H. Functional characterization of a P. falcipamm cyclin homologue. J. Biol. Chem. (2000) 275:8952–8958.
   Google Scholar
• •Describes regulatory mechanisms of the plasmodial CDKs.
   Google Scholar
• LI JL, ROBS ON KJ, CHEN JL et al.: Pfmrk, a M015-related protein kinase from Plasmodium fakipamm. Gene cloning, sequence, stage-specific expression and chromosome localization. Eur: Biochem. (1996) 241:805–813.
   Google Scholar
• WATERS NC, WOODARD CL, PRIGGE ST: Cyclin H activation and drug susceptibility of the Pfmrk cyclin-dependent protein kinase from Plasmodium fakiparum. Biochem. Parasitol (2000) 107:45–55.
   PubMed Web of Science ®Google Scholar
• ••Describes a molecular model that explainsthe failure of olomoucine to inhibit Pfmrk.
   Google Scholar
• SHUTTLEWORTH J: The regulation and functions of cdk7. Frog. Cell Cycle Res. (1995) 1:229–240.
   PubMedGoogle Scholar
• SERIZAWA H, MAKELA TP, CONAWAY JVV et al: Association of Cdk-activating kinase subunits with transcription factor TFIIH. Nature (1995) 374:280–282.
   PubMed Web of Science ®Google Scholar
• KALDIS P, SUTTON A, SOLOMON MJ: The Cdk-activating kinase (CAK) from budding yeast. Cell (1996) 86:553–564.
   PubMed Web of Science ®Google Scholar
• KALDIS P, RUSSO AA, CHOU HS et al.: Human and yeast cdk-activating kinases (CAKs) display distinct substrate specificities. Ma Biol. Cell (1998) 9:2545–2560.
   PubMed Web of Science ®Google Scholar
• CISMOWSKI MJ, LAFF GM, SOLOMON MJ et al.: KIN28 encodes a C-terminal domain kinase that controls mRNA transcription in Saccharomyces cerevisiae but lacks cyclin-dependent kinase-activating kinase (CAK) activity. Ma Cell. Biol. (1995) 15:2983–2992.
   Google Scholar
• LIZ, LE ROCH K, GEYER JA et al: Influence of human p16(INK4) and p21(CIP1) on the M vitro activity of recombinant Plasmodium fakiparum cyclin-dependent protein kinases. Biochem. Biophys. Res. Commun. (2001) 288:1207–1211.
   PubMed Web of Science ®Google Scholar
• •Describes regulatory mechanisms of the plasmodial CDKs.
   Google Scholar
• BROWN NR, NOBLE ME, LAWRIE AM et al.: Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity. Biol. Chem. (1999) 274:8746–8756.
   Web of Science ®Google Scholar
• RUSSO AA, JEFFREY PD, PAVLETICH NP: Structural basis of cyclin-dependent kinase activation by phosphorylation. Nat. Struct. Biol. (1996) 3:696–700.
   PubMedGoogle Scholar
• HARMSE L, VAN ZYL R, GRAY N et al.: Structure-activity relationships and inhibitory effects of various purine derivatives on the M vitro growth of Plasmodium fakiparum. Biochem. Pharmacol. (2001) 62:341–348.
   PubMed Web of Science ®Google Scholar
• HONMA T, YOSHIZUMI T, HASHIMOTO N et al.: A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues. I Med. Chem. (2001) 44:4628–4640.
   PubMed Web of Science ®Google Scholar
• ••Describes the development of specificCDK inhibitors.
   Google Scholar
• VESELY J, HAVLICEK L, STRNAD M et al.: Inhibition of cyclin-dependent kinases by purine analogues. Ear: Biochem. (1994) 224:771–786.
   PubMedGoogle Scholar
• SIELECKI TM, BOYLAN JF, BENFIELD PA et al.: Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. " Med. Chem. (2000) 43:1–18.
   Google Scholar
• ARRIS CE, BOYLE FT, CALVERT AH et al.: Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. " Med. Chem. (2000) 43:2797–2804.
   Google Scholar
• BARVIAN M, BOSCHELLI DH, COSSROW J et al.: Pyrido [2,3-dlpyrimidin-7-one inhibitors of cyclin-dependent kinases. j. Med. Chem. (2000) 43:4606–4616.
   PubMed Web of Science ®Google Scholar
• SONI R, MULLER L, FURET P et al.: Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product. Biochem. Biophys. Res. Commun. (2000) 275:877–884.
   PubMed Web of Science ®Google Scholar
• IKUTA M, KAMATA K, FUKASAWA K et al.: Crystallographic approach to identification of cyclin-dependent kinase 4 (CDK4)-specific inhibitors by using CDK4 mimic CDK2 protein. J. Biol. Chem. (2001) 276:27548–27554.
   PubMed Web of Science ®Google Scholar
• BRAMSON HN, CORONA J, DAVIS ST et al.: adndole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis. Med. Chem. (2001) 44:4339–4358.
   Web of Science ®Google Scholar
• HONMA T, HAYASHI K, AOYAMA T et al.: Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design." Med. Chem. (2001) 44:4615–4627.
   Google Scholar
• ••Describes an approach to the developmentof specific CDK inhibitors.
   Google Scholar
• NOBLE ME, ENDICOTT JA: Chemical inhibitors of cyclin-dependent kinases: insights into design from X-ray crystallographic studies. Pharmacol. (1999) 82:269–278.
   Web of Science ®Google Scholar
• •Explains the binding of inhibitors within the active site of CDKs.
   Google Scholar
• SENDEROWICZ AM, SAUSVILLE EA: Preclinical and clinical development of cyclin-dependent kinase modulators.' Nati Cancer Inst. (2000) 92:376–387.
   PubMed Web of Science ®Google Scholar
• DAVIS ST, BENSON BG, BRAMSON HN et al.: Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors. Science (2001) 291:134–137.
   PubMed Web of Science ®Google Scholar
• DE AZEVEDO WF, LECLERC S, MEIJER L et al.: Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Ear: Biochem. (1997) 243:518–526.
   PubMedGoogle Scholar
• XIAO Z, WATERS NC, WOODARD CL et al.: Design and synthesis of Pfmrk inhibitors as potential antimalarial agents. Bioorg. Med. Chem. Lett (2001) 11:2875–2878.
   PubMed Web of Science ®Google Scholar
• LI R, CHEN X, GONG B et al.: Structure-based design of parasitic protease inhibitors. Bioorg. Med. Chem. (1996) 4:1421–1427.
   PubMed Web of Science ®Google Scholar
• LI R, KENYON GL, COHEN FE et al.: In vitroantimalarial activity of chalcones and their derivatives. Med. Chem. (1995) 38:5031–5037.
   Web of Science ®Google Scholar
• LIU M, WILAIRAT P, GO ML: Antimalarial alkoxylated and hydroxylated chalcones: structure-activity relationship analysis. J. Med. Chem. (2001) 44:4443–4452.
   PubMed Web of Science ®Google Scholar
• DOMINGUEZ JN, CHARRIS JE, LOBO G et al.: Synthesis of quinolinyl chalcones and evaluation of their antimalarial activity. Ear: I Med. Chem. (2001) 36:555–560.
   PubMed Web of Science ®Google Scholar
• SUROLIA N, SUROLIA A:Triclosan offersprotection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum. Nat. Med. (2001) 7:167–173.
   PubMed Web of Science ®Google Scholar